These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 3823774)
21. Maximal androgen blockade versus total androgen suppression. Dumez H; Van Poppel H; Baert L; Paridaens R Acta Urol Belg; 1997 Mar; 65(1):49-54. PubMed ID: 9175283 [TBL] [Abstract][Full Text] [Related]
22. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist. Boudreaux KJ; Chang SS BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172 [No Abstract] [Full Text] [Related]
23. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749 [TBL] [Abstract][Full Text] [Related]
24. Endocrine therapy for prostate cancer. Damber JE Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920 [TBL] [Abstract][Full Text] [Related]
25. Hormonal treatment in prostate cancer. Zbranca E; Preda C Endocrinologie; 1991; 29(1-2):91-7. PubMed ID: 1803495 [TBL] [Abstract][Full Text] [Related]
26. [Hormone therapy for prostate cancer]. Théodore C Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807 [TBL] [Abstract][Full Text] [Related]
28. [Prostatic cancer]. Yoshida O; Oishi K; Arai Y; Mori H Gan To Kagaku Ryoho; 1989 Dec; 16(12):3704-11. PubMed ID: 2688560 [TBL] [Abstract][Full Text] [Related]
30. Intra-prostatic androgen levels during various androgen-blockade regimens. Nishiyama T Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782 [TBL] [Abstract][Full Text] [Related]
31. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer]. Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959 [TBL] [Abstract][Full Text] [Related]
32. [Prostatic cancer and its androgen-dependency]. Shimazaki J; Isaka S; Akimoto S; Sumiya H; Ichikawa T; Akakura K; Furuya Y Gan No Rinsho; 1989 May; Spec No():268-76. PubMed ID: 2513430 [No Abstract] [Full Text] [Related]
33. Hormone-refractory prostate cancer: what have we learned? Wirth MP BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362 [No Abstract] [Full Text] [Related]
34. Hormonal implications in the development and treatment of prostate cancer. Ip C; Hall SJ Endocrinol Metab Clin North Am; 2007 Jun; 36(2):421-34. PubMed ID: 17543727 [TBL] [Abstract][Full Text] [Related]
35. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Middleman MN; Lush RM; Figg WD Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595 [TBL] [Abstract][Full Text] [Related]
36. Treating prostate cancer. Part V: androgen deprivation and chemotherapy. Harv Mens Health Watch; 1999 Dec; 4(5):5-8. PubMed ID: 10564905 [No Abstract] [Full Text] [Related]
37. Hormonal therapy for stage D cancer of the prostate. Gudziak MR; Smith AY West J Med; 1994 Apr; 160(4):351-9. PubMed ID: 8023485 [TBL] [Abstract][Full Text] [Related]
38. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate]. Lopez S; Simon JM; Mazeron JJ Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304 [TBL] [Abstract][Full Text] [Related]
39. Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer. Nicholson RI; Walker KJ; Davies P Cancer Surv; 1986; 5(3):463-86. PubMed ID: 3555778 [No Abstract] [Full Text] [Related]